2022-05-10T08:00:00Z – Publication of Biohit Oyj Renumeration Report 2021
2022-05-09T11:00:00Z – Recent study from Japan confirms the value of original GastroPanel® biomarkers diagnosis of autoimmune atrophic gastritis.
2022-03-30T06:30:00Z – Publication of Biohit Oyj Annual Report 2021
2022-03-10T08:00:00Z – Biohit Oyj Extraordinary general meeting and board of directors meeting decisions
2022-02-16T07:30:00Z – BIOHIT GROUP FINANCIAL STATEMENT RELEASE 2021
2022-02-15T08:00:00Z – NEW RECOMMENDATION BY THE MINISTRY OF HEALTH OF THE RUSSIAN FEDERATION: All patients with suspected gastritis should be examined by Pepsinogen I, Pepsinogen II and Gastrin-17 biomarkers.
2022-02-09T12:00:00Z – Notice of Biohit Oyj's extraordinary general meeting
2022-02-08T12:00:00Z – Biohit has settled the dispute concerning a breach of the patent license agreement and therefore specifies its financial guidance for 2021
2022-01-18T13:00:00Z – Biohit Oyj Managers' Trancactions - Elomaa
2022-01-18T13:00:00Z – Biohit Oyj - Managers' Transactions - Hahtela
2022-01-18T13:00:00Z – Biohit Oyj - Managers' Transactions - Mäki
2022-01-18T13:00:00Z – Biohit Oyj - Managers' Transactions - Patrakka
2022-01-18T13:00:00Z – Biohit Oyj - Managers' Transactions - Siltala
2022-01-18T13:00:00Z – Biohit Oyj - Managers' Transactions - Söderström
2022-01-13T12:30:00Z – Biohit Oyj’s Financial Reporting and Annual General Meeting in 2022
2021-12-14T08:00:00Z – Recent clinical validation study confirms the accuracy of the new-generation GastroPanel® test in diagnosis of atrophic gastritis and Helicobacter pylori infection.
2021-12-09T12:00:00Z – Biohit Oyj Board of Directors decided on new option scheme
2021-08-11T06:30:00Z – Biohit Group Half Year Financial Report 2021
2021-08-10T13:15:00Z – CE marked GastroPanel® quick test on the market
2021-07-29T06:00:00Z – Päivi Siltala new CEO of Biohit Oyj
2021-06-29T06:30:00Z – Constitutive meeting of Biohit Oyj’s Board of Directors
2021-06-28T11:01:00Z – Changes in Management Team
2021-06-23T12:45:00Z – Decisions of the Annual General Meeting of Biohit Oyj
2021-05-28T11:00:00Z – Notice of Biohit Oyj’s annual general meeting
2021-05-28T11:00:00Z – Publication of Biohit Oyj Renumeration Report 2020
2021-05-24T10:30:00Z – Changes to Biohit Oyj’s management
2021-05-21T11:30:00Z – Changes to Biohit Oyj’s management
2021-05-17T15:30:00Z – Biohit Oyj’s President and CEO Semi Korpela to leave the company
2021-05-17T15:30:00Z – Biohit corporation initiates arbitration proceedings concerning a breach of the license agreement
2021-04-26T07:59:18Z – Biohit Oyj comments on the claims presented in public by a member of Biohit board of directors, Mr. Liu Feng
2021-04-20T10:00:00Z – A study from Italy confirms: Low levels of G-17 biomarker of the Biohit GastroPanel® test predict the risk of esophagitis and esophageal reflux disease (GERD)
2021-04-08T10:00:00Z – Austell Pharmaceuticals starts as a new distributor of Biohit Oyj’s GastroPanel[®] test in South Africa
2021-03-26T13:35:00Z – Publication of Biohit Oyj Annual Report 2020
2021-03-26T07:01:02Z – Biohit’s CEO is on sick leave
2021-03-08T08:00:00Z – European Union and Business Finland provide Biohit Oyj with a total of EUR 900,000 in financing for product development
2021-03-03T15:00:00Z – Biohit Plc - Managers' transactions - Aiolfi
2021-03-03T15:00:00Z – Biohit Plc - Managers' transactions - Aiolfi
2021-02-23T08:02:16Z – Biohit Oyj Managers' Transactions
2021-02-17T07:30:00Z – Biohit group financial statement release 2020
2020-12-14T07:30:00Z – TPX Medik appointed as the exclusive distributor of GastroPanel® test in Malaysia
2020-12-09T12:30:00Z – Biohit Oyj’s Financial Reporting and Annual General Meeting in 2021
2020-09-25T12:00:00Z – Biohit GastroPanel[®] test was studied clinically in patients with autoimmune disease
2020-09-16T15:48:39Z – Correction: Decisions of the Annual General Meeting of Biohit Oyj
2020-09-16T15:00:00Z – Constitutive meeting of Biohit Oyj’s Board of Directors
2020-09-16T12:30:00Z – Decisions of the Annual General Meeting of Biohit Oyj
2020-08-21T14:30:00Z – Notice of Biohit oyj’s annual general meeting
2020-08-12T06:30:00Z – Biohit group half year financial report 2020
2020-08-06T07:05:00Z – The usefulness of Biohit GastroPanel[®] biomarkers in diagnosis of atrophic gastritis confirmed in a multi-center study in France
2020-06-04T15:00:00Z – Biohit Group’s Net Sales outlook for 2020 changed
2020-04-15T07:03:40Z – Does an undiagnosed atrophic gastritis (acid-free stomach) increase the risk of coronavirus infection, its complications and mortality particularly among elderly people?